Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.

Androgen deprivation therapy: past, present and future.

Schröder F, Crawford ED, Axcrona K, Payne H, Keane TE.

BJU Int. 2012 Jun;109 Suppl 6:1-12. doi: 10.1111/j.1464-410X.2012.11215.x. Review.

2.

Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.

Van Poppel H, Klotz L.

Int J Urol. 2012 Jul;19(7):594-601. doi: 10.1111/j.1442-2042.2012.02997.x. Epub 2012 Mar 14. Review.

3.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
4.

[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].

Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A.

Actas Urol Esp. 2011 Nov-Dec;35(10):565-79. doi: 10.1016/j.acuro.2011.03.011. Epub 2011 Jul 14. Spanish.

PMID:
21757258
5.

Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.

Axcrona K, Aaltomaa S, da Silva CM, Ozen H, Damber JE, Tankó LB, Colli E, Klarskov P.

BJU Int. 2012 Dec;110(11):1721-8. doi: 10.1111/j.1464-410X.2012.11107.x. Epub 2012 Apr 13.

6.

Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy.

Schulman C, Irani J, Aapro M.

BJU Int. 2012 Jun;109 Suppl 6:13-21. doi: 10.1111/j.1464-410X.2012.11216.x. Review.

7.

New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.

Shore ND, Abrahamsson PA, Anderson J, Crawford ED, Lange P.

Prostate Cancer Prostatic Dis. 2013 Mar;16(1):7-15. doi: 10.1038/pcan.2012.25. Epub 2012 Jul 3. Review.

PMID:
22751146
8.

Is the flare phenomenon clinically significant?

Bubley GJ.

Urology. 2001 Aug;58(2 Suppl 1):5-9. Review.

PMID:
11502435
9.
10.

Endocrine treatment of prostate cancer.

Tammela T.

J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. Epub 2004 Dec 31. Review.

PMID:
15663992
11.

Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.

Klotz L, Miller K, Crawford ED, Shore N, Tombal B, Karup C, Malmberg A, Persson BE.

Eur Urol. 2014 Dec;66(6):1101-8. doi: 10.1016/j.eururo.2013.12.063. Epub 2014 Jan 9.

PMID:
24440304
12.

Degarelix: a new approach for the treatment of prostate cancer.

Persson BE, Kold Olesen T, Jensen JK.

Neuroendocrinology. 2009;90(3):235-44. doi: 10.1159/000228832. Epub 2009 Jul 14.

PMID:
19602868
13.

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.

Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH.

BJU Int. 2008 Dec;102(11):1531-8. doi: 10.1111/j.1464-410X.2008.08183.x.

14.

Neoadjuvant flutamide monotherapy for locally confined prostate cancer.

Yoshimura K, Sumiyoshi Y, Hashimura T, Ueda T, Kamiryo Y, Yamamoto A, Arai Y.

Int J Urol. 2003 Apr;10(4):190-5.

16.
17.

Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.

Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, Bremner WJ, Gleave ME, Nelson PS.

Cancer Res. 2007 May 15;67(10):5033-41.

18.

Management of advanced prostate cancer: can we improve on androgen deprivation therapy?

Anderson J, Abrahamsson PA, Crawford D, Miller K, Tombal B.

BJU Int. 2008 Jun;101(12):1497-501. doi: 10.1111/j.1464-410X.2008.07590.x. Epub 2008 Mar 11. Review.

19.

Failure to achieve a PSA level <or=1 ng/mL after neoadjuvant LHRHa therapy predicts for lower biochemical control rate and overall survival in localized prostate cancer treated with radiotherapy.

Mitchell DM, McAleese J, Park RM, Stewart DP, Stranex S, Eakin RL, Houston RF, O'Sullivan JM.

Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1467-71. Epub 2007 Aug 8.

PMID:
17689886
20.

Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).

Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR; CaPSURE Investigators.

Cancer. 2006 Apr 15;106(8):1708-14.

Supplemental Content

Support Center